Posted: DEC 03, 2007

CSMG Technologies Live Tissue Connect Subsidiary Receives CE Mark for New VAD.400 RF Generator

Corpus Christi, TX, December 03, 2007 -- CSMG Technologies, Inc., (OTCBB: CTUM - News), President and CEO Donald S. Robbins today announced its subsidiary, Live Tissue Connect ("LTC"), received CE Mark certification for its new VAD.400 RF Generator.

"We at CSMG Technologies are extremely pleased to announce that our subsidiary Live Tissue Connect's generator has received the ability to be CE Marked. This important milestone allows the generator to be sold in Europe. This is a major step toward launching the entire VAD-400 handpiece and generator system into the European markets. Presently we are evaluating multiple distribution options, both in the U.S. and internationally," said Mr. Robbins.

LTC's Frank D'Amelio commented, "Being in compliance with all applicable IEC60601 and MDD test regulations is a significant accomplishment, it’s the result of the hard work of the LTC team and our generator manufacturing company. We're proud to receive such compliance notification from TUV Nord. Our next step will be to obtain a CE Mark for our disposable handpieces. We know that there is a huge market in Europe for our generator and the instruments it will support. Passing the CE Mark examination is a major requirement to address this market."

Mr. Robbins added, “LTC is attracting interest from many significant medical device companies and distributors interested in representing, licensing, and/or marketing some aspect of the LTC technology. Each LTC wholly-owned subsidiary represents a distinct manufacturing, marketing, or licensing opportunity, and represents a major commercial opportunity for our company.”

The CE mark is required only in the countries of the European Economic Area (EEA) and in Turkey. The EEA is formed by the 27 Member States of the European Union (EU) and the three members of the European Free Trade Association (EFTA); Iceland, Norway and Liechtenstein.

LTC has identified 12 procedure-specific divisions and established the first six regarded as closest to product and market completion. This subsidiary structure allows the company to leverage LTC's R&D across multiple medical disciplines. As an example, the R&D effort that went into developing a sealing device for gynecological arteries and veins might be leveraged into a similar device for urological procedures though would likely be different in shape and/or size. This structure also lets potential marketing partner's select surgical specialties where they have strong physician relationships and/or pre-existing distribution channels.

“Presently we are evaluating multiple distribution options both in the U.S. and internationally," continued Mr. Robbins.

About CSMG Technologies, Inc

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 40 patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT:

CSMG Technologies, Inc.
Donald S. Robbins, President and CEO
361-887-7546
or
K. Bruce Jones, 770-955-0409
or
ROI Group Associates, Inc.
Michael Dodge, 212-495-0744
mdodge@roiny.com